- Home
- ANVS vs IPHA Comparison
ANVS vs IPHA Comparison
Compare ANVS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | IPHA |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 119.1M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANVS | IPHA |
|---|---|---|
| Price | $2.22 | $1.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $13.50 | $5.75 |
| AVG Volume (30 Days) | ★ 382.7K | 13.7K |
| Earning Date | 03-16-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $28.31 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $1.18 |
| 52 Week High | $5.50 | $2.63 |
Technical Indicators
Market Signals| Indicator | ANVS | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 38.52 | 36.95 |
| Support Level | $1.97 | N/A |
| Resistance Level | $2.29 | $1.88 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 1.08 | 25.53 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.